Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06643728 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

A Phase 2 study of Obesity and Overweight, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 2
Development phase
240
Enrollment target
12
Study locations

NCT06643728: Active Phase 2 study of Obesity and Overweight, sponsored by Eli Lilly and Company.

NCT06643728 is a Phase 2 study of Obesity and Overweight that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 240 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (71% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06643728, a Phase 2 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
240 participants
Enrollment target
12
Study locations

Study Summary

The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.

Conditions Studied

Obesity Overweight

Interventions

  • DRUG Tirzepatide
  • DRUG Bimagrumab
  • DRUG Bimagrumab Placebo
  • DRUG Tirzepatide Placebo

Study Locations (12)

Florida

  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare - Jacksonville
  • Altus Research - Lake Worth
  • Suncoast Research Group - Miami

Alabama

  • Pinnacle Research Group, LLC - Anniston
  • Central Research Associates - Birmingham

Washington

  • Eastside Research Associates - Redmond
  • Rainier Clinical Research Center - Renton

California

  • Diablo Clinical Research, Inc. - Walnut Creek

Hawaii

  • East-West Medical Research Institute - Honolulu

Illinois

  • Great Lakes Clinical Trials - Ravenswood - Chicago

Mississippi

  • SKY Integrative Medical Center/SKYCRNG - Ridgeland

Pennsylvania

  • Keystone Clinical Studies - Plymouth Meeting

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2024-10-21
Est. Completion 2027-01
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06643728

The ClinicalTrials.gov registry entry for NCT06643728 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (71% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Tirzepatide is the first listed.

NCT06643728 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Florida, Alabama, Washington.

Frequently Asked Questions

What is clinical trial NCT06643728 about?

NCT06643728 is a clinical study titled "A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight". The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.

What is the current status of trial NCT06643728?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2024-10-21. Estimated completion is 2027-01.

What conditions does trial NCT06643728 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT06643728?

The interventions under investigation include: Tirzepatide (DRUG), Bimagrumab (DRUG), Bimagrumab Placebo (DRUG), Tirzepatide Placebo (DRUG).

Who is sponsoring clinical trial NCT06643728?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06643728 being conducted?

This trial has 12 study locations across Alabama, California, Florida, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.